ScreenerHero

ETRA Electra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · electra-therapeutics.com
7.350USD-7.78%Mkt Cap: 461.34M $P/E: —

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated disease…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$137.54BUSDP/E 34.9
MRNA
Moderna, Inc.
$96.40BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$93.40BUSDP/E 20.0
CSL
CSL Limited
$68.14BUSD
UCB
UCB SA
$62.34BUSDP/E 25.6
ARGX
argenx SE
$57.79BUSDP/E 32.8
ARGX
argenx SE
$56.27BUSDP/E 31.0
ONC
BeOne Medicines AG
$44.06BUSDP/E 69.3
RPRX
Royalty Pharma plc
$39.04BUSDP/E 44.2
RVMD
Revolution Medicines, Inc.
$38.08BUSD
GMAB
Genmab A/S
$33.70BUSDP/E 44.8
GMAB
Genmab A/S
$32.43BUSDP/E 41.5
ROIV
Roivant Sciences Ltd.
$26.45BUSD
INCY
Incyte Corporation
$24.05BUSDP/E 60.2
INSM
Insmed Incorporated
$23.86BUSD
BNTX
BioNTech SE
$21.29BUSD
ALNY
Alnylam Pharmaceuticals, Inc.
$20.98BUSDP/E 7.9
EXEL
Exelixis, Inc.
$16.77BUSDP/E 20.6
ASND
Ascendis Pharma A/S
$16.68BUSDP/E 19.4
JAZZ
Jazz Pharmaceuticals plc
$14.59BUSDP/E 67.3
Insiders, last 90 days2 buys
Institutional holders1 on file

Key Statistics

Company
Market Cap461.34M USD
Enterprise Value663.91M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-61.98M USD
Revenue/Share—
Last Price7.350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.09
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-2.65
EPS (Forward)-1.80
52W Range
6.8805% of range15.50
52W High15.50 USD
52W Low6.880 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE204.36%
ROA-62.37%
ROIC—
ROCE-69.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.48M USD
CapEx (TTM)733.00K USD
FCF Margin—
FCF Yield—
Net Debt-95.74M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.07
Current Ratio7.37
Quick Ratio7.19
Book Value/Sh-4987.61 USD
Cash/Share1.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.20 USD
Upside (mean)+351.7%
Target Range30.00 USD – 36.00 USD
30.00+351.7% to mean36.00
# Analysts5
Ownership
Shares Out.62.77M
Float29.12M
Insiders1.37%
Institutions40.57%
Short Interest
Short Ratio0.5d
Short % Out.0.65%
Shares Short409.38K
Technical
SMA 509.808 (-25.1%)
SMA 2009.808 (-25.1%)
Beta—
S&P 52W Chg14.41%
Avg Vol (30d)455.19K
Avg Vol (10d)292.23K
Technical Indicators
RSI (14)29.3
MACD-0.8347
MACD Signal-0.8541
MACD Hist.+0.0194
BB Upper9.670 USD
BB Middle8.557 USD
BB Lower7.445 USD
BB Width26.00%
ATR (14)0.9071 USD
Vol Ratio (20d)1.36x